Neuphoria Therapeutics (NEUP) Receivables - Net (2020 - 2026)
Neuphoria Therapeutics (NEUP) reported Receivables - Net of $1.6 million for Q1 2026, up 6427.9% year-over-year from $24592.0 in Q1 2025, and up 44.64% on a QoQ basis from $1.1 million in Q4 2025.
Neuphoria Therapeutics (NEUP) has 7 years of Receivables - Net data on file, last reported at $1.6 million in Q1 2026.
- Quarterly Receivables - Net rose 6427.9% year-over-year to $1.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 million (up 6427.9% YoY) and the FY2025 annual result came in at $11948.0, down 90.58% from the prior year.
- Receivables - Net advanced to $1.6 million in Q1 2026 per NEUP's latest filing, from $1.1 million in the prior quarter.
- Across five years, Receivables - Net topped out at $4.9 million in Q2 2022 and bottomed at $1758.0 in Q3 2025.
- The 5-year median for Receivables - Net is $75760.5 (2024), against an average of $790103.9.
- The widest annual swing landed in 2023, when Receivables - Net slumped 99.8%; it then jumped 6427.9% in 2026.
- Tracing NEUP's Receivables - Net over 5 years: stood at $4.9 million in 2022, then tumbled by 99.8% to $9836.9 in 2023, then soared by 261.51% to $35561.0 in 2024, then soared by 3021.14% to $1.1 million in 2025, then surged by 44.64% to $1.6 million in 2026.
- Per Business Quant, the three latest NEUP Receivables - Net figures stand at $1.6 million (Q1 2026), $1.1 million (Q4 2025), and $1758.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Neuphoria Therapeutics | 28.35 Mn | 8.95 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.61 Mn |
| Mar 31, 2026 | 1.61 Mn |
| Dec 31, 2025 | 1.11 Mn |
| Dec 31, 2025 | 1.11 Mn |
| Sep 30, 2025 | 1,758.00 |
| Sep 30, 2025 | 1,758.00 |
| Jun 30, 2025 | 11,948.00 |
| Jun 30, 2025 | 11,948.00 |
| Mar 31, 2025 | 24,592.00 |
| Mar 31, 2025 | 24,592.00 |
| Dec 31, 2024 | 35,561.00 |
| Dec 31, 2024 | 35,561.00 |
| Sep 30, 2024 | 115,960.00 |
| Sep 30, 2024 | 115,960.00 |
| Jun 30, 2024 | 126,884.00 |
| Jun 30, 2024 | 126,884.00 |
| Jun 30, 2023 | 9,836.93 |
| Jun 30, 2023 | 9,836.93 |
| Jun 30, 2022 | 4.86 Mn |
| Jun 30, 2022 | 4.86 Mn |
| Jun 30, 2021 | 868,841.66 |
| Jun 30, 2021 | 868,841.66 |
| Jun 30, 2020 | 686,395.15 |
| Jun 30, 2020 | 686,395.15 |